natgillin/translations-raw huggingface dataset:
Bone toxicity was observed as reduced bone mineral density in rats and dogs at tenofovir exposures at least four times greater than those expected after administration of Symtuza. 
Toksičnost za kost manifestirala se kao smanjena mineralna gustoća kosti u štakora i pasa pri izloženostima tenofoviru najmanje četiri puta većima od onih očekivanih nakon primjene lijeka Symtuza.
The safety and efficacy of Symtuza or its components have not been established in patients with severe underlying liver disorders. 
Sigurnost i djelotvornost lijeka Symtuza ili njegovih sastavnica u bolesnika s teškim poremećajima jetrene funkcije nisu ustanovljene.
Symtuza should be discontinued in patients with eGFRCG that declines below 30 mL/min during treatment (see sections 5.1 and 5.2). 
Liječenje lijekom Symtuza treba prekinuti u bolesnika u kojih eGFRCG tijekom liječenja padne ispod 30 ml/min (vidjeti dijelove 5.1 i 5.2).
The pharmacologically active metabolite, tenofovir diphosphate, has a half-life of 150-180 hours within PBMCs. 
Poluvijek farmakološki aktivnog metabolita, tenofovirdifosfata, u mononuklearnim stanicama periferne krvi iznosi 150 - 180 sati.
Based on stratum adjusted MH test where stratification factors are HIV-1 RNA level (≤ 100,000 or > 100,000 copies/mL) and CD4+ cell count (< 200 or ≥ 200 cells/µL). 
Temeljeno na MH testu prilagođenom prema stratumu gdje su stratifikacijski faktori razina HIV-1 RNK (≤100 000 ili > 100 000 kopija/mL) i broj CD4+ stanica (< 200 ili ≥200 stanica/µL).
- lopinavir/ritonavir - St. John's wort (Hypericum perforatum) 
- lopinavir/ritonavir - gospina trava (Hypericum perforatum)
ANTIFUNGALS Clotrimazole Fluconazole Itraconazole 
ANTIMIKOTICI Klotrimazol Flukonazol Itrakonazol
H2-RECEPTOR ANTAGONISTS Cimetidine 
ANTAGONISTI H2 RECEPTORA
PROTON PUMP INHIBITORS Dexlansoprazole 
INHIBITORI PROTONSKE PUMPE Dekslanzoprazol
Treatment with darunavir/cobicistat 800/150 mg during the second and third trimester has been shown to result in low darunavir exposure, with a reduction of around 90% in Cmin levels (see section 5.2). 
Liječenje darunavirom/kobicistatom 800/150 mg tijekom drugog i trećeg tromjesečja rezultiralo je niskom izloženošću darunaviru, sa smanjenjem od otprilike 90% Cmin razina (vidjeti dio 5.2).
FDA Snapshot Outcome HIV-1 RNA < 50 copies/mL Virologic Failure 
FDA Snapshot ishod HIV-1 RNK < 50 kopija/mL Virološki neuspjeh
The recommended dose regimen in adults and adolescents aged 12 years and older, weighing at least 40 kg, is one tablet taken once daily with food. 
Preporučeni režim doziranja u odraslih i adolescenata u dobi od 12 godina i starijih, tjelesne težine od najmanje 40 kg, je jedna tableta jedanput na dan, s hranom.
During the darunavir/ritonavir clinical development program (N = 3,063), severe skin reactions, which may be accompanied with fever and/or elevations of transaminases, have been reported in 0.4% of patients. 
Tijekom programa kliničkog razvoja darunavira/ritonavira (N = 3063) u 0,4% bolesnika prijavljene su teške kožne reakcije, koje mogu biti praćene vrućicom i/ili povišenim vrijednostima transaminaza.
At Week 48 changes from baseline were smaller with D/C/F/TAF than D/C+F/TDF. 
Promjene od početne vrijednosti u 48. tjednu bile su manje uz D/K/F/TAF nego uz D/K+F/TDF.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment (see section 4.4). 
Prijavljeni su i autoimuni poremećaji (poput Gravesove bolesti i autoimunog hepatitisa); međutim, prijavljeno vrijeme do njihova nastupa je varijabilno, pa se oni mogu javiti i više mjeseci nakon početka liječenja (vidjeti dio 4.4).
The emtricitabine-resistant virus with the M184M/I/V mutation was cross-resistant to lamivudine, but retained sensitivity to abacavir, stavudine, tenofovir, and zidovudine. 
Virus rezistentan na emtricitabin s mutacijom M184M/I/V bio je križno rezistentan na lamivudin, ali je zadržao osjetljivost na abakavir, stavudin, tenofovir i zidovudin.
For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. 
Za nadzor lipida i glukoze u krvi postoje preporuke u utvrđenim smjernicama za liječenje HIV-a.
Store in the original package with desiccant inside the bottle in order to protect the tablets from moisture. 
Čuvati u originalnom pakiranju sa sredstvom za sušenje u boci radi zaštite tableta od vlage.
Unchanged darunavir accounted for approximately 41.2% and 7.7% of the administered dose in faeces and urine, respectively. 
Nepromijenjen darunavir činio je približno 41,2% primijenjene doze u fecesu, odnosno 7,7% primijenjene doze u mokraći.
Nervous system disorders very common headache common dizziness 
Poremećaji živčanog sustava vrlo često glavobolja često omaglica
Isavuconazole Posaconazole 
Izavukonazol Posakonazol
Some late-onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour). 
Prijavljeni su i neki neurološki poremećaji s odgođenim nastupom (hipertonija, konvulzije, neuobičajeno ponašanje).
Expected interactions between Symtuza with potential concomitant medicinal products are listed in Table 1 below and are based on the studies conducted with the components of Symtuza, as individual agents or combined, or are potential drug interactions that may occur. 
Očekivane interakcije između lijeka Symtuza i mogućih istodobno primijenjenih lijekova navedene su u Tablici 1 u nastavku i temelje se na ispitivanjima provedenima sa sastavnicama lijeka Symtuza primijenjenima zasebno ili u kombinaciji, ili predstavljaju moguće interakcije između lijekova.
In vivo, darunavir resistance-associated mutations (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V and L89V) in HIV-1 protease were derived from clinical trial data of ART-experienced patients, all of whom were protease inhibitor experienced. 
In vivo, mutacije proteaze virusa HIV-1 povezane s rezistencijom na darunavir (V11I, V32I, L33F, I47V, I50V, I54L ili M, T74P, L76V, I84V i L89V) temelje se na podacima iz kliničkih ispitivanja provedenih u bolesnika prethodno liječenih antiretrovirusnom terapijom, od kojih su svi prethodno primali inhibitor proteaze.
During the darunavir/ritonavir clinical development program (N = 3,063), hepatitis was reported in 0.5% of patients receiving combination antiretroviral therapy with darunavir/ritonavir. 
Tijekom programa kliničkog razvoja (N = 3063), hepatitis je prijavljen u 0,5% bolesnika koji su primali kombiniranu antiretrovirusnu terapiju darunavirom/ritonavirom.
Baseline viral load ≤ 100,000 copies/mL > 100,000 copies/mL 
Početna vrijednost virusnog opterećenja ≤100 000 kopija/mL >100 000 kopija /mL
After 96 weeks of treatment with Symtuza, the (95% CI) percent changes from baseline in BMD at the hip and spine region were respectively: -0.26 (-0.96; 0.45) % and -0.93 (-1.82; -0.05) %. 
Nakon 96 tjedana liječenja lijekom Symtuza, postotna promjena (95% CI) početne mineralne gustoće kostiju na području kuka i kralježnice iznosila je -0,26 (-0,96; 0,45) % odnosno -0,93 (-1,82; -0,05) %.
Pantoprazole 
Pantoprazol
In vitro and clinical pharmacokinetic drug-drug interaction studies have shown that the potential for CYP-mediated interactions involving emtricitabine with other medicinal products is low. 
Ispitivanja in vitro te klinička ispitivanja farmakokinetičkih interakcija između lijekova pokazala su malu mogućnost interakcija emtricitabina s drugim lijekovima u kojima posreduju enzimi CYP.
- Colchicine (antigout). 
- kolhicin (za liječenje gihta).
Genotypic testing should guide the use of Symtuza (see sections 4.2, 4.4, and 5.1). 
Kod primjene lijeka Symtuza treba se voditi genotipskim pretragama (vidjeti dijelove 4.2, 4.4 i 5.1).
There is no specific antidote for overdose with Symtuza. 
Nema specifičnog protulijeka za predoziranje lijekom Symtuza.
In some patients with advanced liver disease or cirrhosis, stopping treatment may lead to worsening of hepatitis, which may be life-threatening. 
U nekih bolesnika s uznapredovalom jetrenom bolešću ili cirozom prekid liječenja može dovesti do pogoršanja hepatitisa, koje može biti opasno po život.
At peak plasma concentration, the mean plasma to blood drug concentration ratio was approximately 1.0 and the mean semen to plasma drug concentration ratio was approximately 4.0. 
Pri vršnoj koncentraciji u plazmi srednja vrijednost omjera koncentracije lijeka između plazme i krvi iznosila je približno 1,0, a srednja vrijednost omjera koncentracije lijeka između sjemena i plazme približno 4,0.
Medicinal products that induce P-gp activity (e.g., rifampicin, rifabutin, carbamazepine, phenobarbital) are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which may lead to loss of therapeutic effect of tenofovir alafenamide and development of resistance. 
Očekuje se da će lijekovi koji induciraju aktivnost P-gp-a (npr. rifampicin, rifabutin, karbamazepin, fenobarbital) smanjiti apsorpciju tenofoviralafenamida te tako uzrokovati sniženje njegove plazmatske koncentracije, što može dovesti do gubitka terapijskog učinka tenofoviralafenamida i razvoja rezistencije.
Cobicistat is 97% to 98% bound to human plasma proteins and the mean plasma to blood-drug concentration ratio was approximately 2. 
Udio kobicistata koji se vezuje za proteine u plazmi ljudi iznosi 97 - 98%, a srednja vrijednost omjera koncentracije lijeka između plazme i krvi iznosila je približno 2.
Darunavir contains a sulphonamide moiety. 
Darunavir sadrži sulfonamidnu komponentu.
The safety of emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet was evaluated in approximately 70 HIV/HBV co-infected patients currently receiving treatment for HIV in an open-label clinical study (GS-US-292-1249). 
Sigurnost emtricitabina i tenofoviralafenamida u kombinaciji s elvitegravirom i kobicistatom u tableti s fiksnom kombinacijom doza ocjenjivala se u približno 70 bolesnika istodobno zaraženih HIV-om i HBV-om koji su u tom trenutku primali liječenje za HIV infekciju u otvorenom kliničkom ispitivanju (GS-US-292-1249).
However, there are pharmacokinetic data for the different components of Symtuza, indicating that doses of 800 mg darunavir, 150 mg cobicistat, 200 mg emtricitabine and 10 mg tenofovir alafenamide result in similar exposures in adults and adolescents aged 12 years and older, weighing at least 40 kg. 
Međutim, postoje farmakokinetički podaci za različite sastavnice lijeka Symtuza, koji pokazuju da doze darunavira od 800 mg, kobicistata od 150 mg, emtricitabina od 200 mg i tenofoviralafenamida od 10 mg dovode do slične izloženosti u odraslih i adolescenata u dobi od 12 ili više godina, tjelesne težine od najmanje 40 kg.
The recommended dose for adults and adolescents 12 years of age and older, who weigh at least 40 kg is one tablet each day with food. 
Preporučena doza u odraslih i adolescenata u dobi od 12 ili više godina i tjelesne težine od najmanje 40 kg je jedna tableta svaki dan s hranom.
Pharmacokinetic results of total darunavir after administration of darunavir/cobicistat 800/150 mg once daily as part of an antiretroviral regimen, during the second trimester of pregnancy, the third trimester of pregnancy, and postpartum Pharmacokinetics of total darunavir (mean ± SD) 
Tablica 8 Farmakinetički rezultati ukupnog darunavira nakon primjene darunavira/kobicistata 800/150 mg jedanput na dan kao dijela antiretrovirusnog režima, tijekom drugog tromjesečja trudnoće, trećeg tromjesečja trudnoće i u postpartalnom razdoblju Farmakinetika ukupnog darunavira (srednja vrijednost ± SD)
There are no pharmacokinetic data on tenofovir alafenamide in patients with eGFRCG < 15 mL/min. 
Nema podataka o farmakokinetici tenofoviralafenamida u bolesnika kojima je eGFRCG < 15 ml/min.
In case of concomitant antiviral therapy for hepatitis B or C, please refer to the relevant product information for these medicinal products. 
U slučaju istodobne primjene antiretrovirusnih lijekova za hepatitis B ili C, vidjeti relevantne informacije o lijeku i za te lijekove.
If there is evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients using Symtuza, interruption or discontinuation of treatment should be considered promptly (see section 5.3). 
Ako se u bolesnika koji uzimaju lijek Symtuza uoče znakovi pojave ili pogoršanja disfunkcije jetre (uključujući klinički značajno povišenje jetrenih enzima i/ili simptome kao što su umor, anoreksija, mučnina, žutica, tamna mokraća, osjetljivost jetre na dodir, hepatomegalija), mora se odmah razmotriti privremen ili trajan prekid liječenja (vidjeti dio 5.3).
The mean increase from baseline in CD4+ cell count at Week 48 was 224 cells/mm 
Srednja vrijednost porasta broja CD4+ stanica u 48. tjednu iznosila je 224 stanice/mm
Patients had no history of virologic failure on darunavir-based regimens, and if historical genotypes were available, absence of darunavir RAMs. 
Bolesnici u anamnezi nisu imali virološki neuspjeh na režimima temeljenima na darunaviru, i ako su bili dostupni povijesni genotipovi, odsutnost mutacija koje su povezane s rezistencijom na darunavir.
6 cells/L), 
6 stanica/L).
Because of both the potential for HIV transmission and the potential for adverse reactions in breast-fed infants, mothers should be instructed not to breast-feed if they are receiving Symtuza. 
Zbog mogućeg prijenosa HIV-a i mogućih nuspojava u dojenčadi na majčinom mlijeku, majke treba uputiti da ne doje ako se liječe lijekom Symtuza.
ANTI-NEOPLASTICS Dasatinib 
ANTINEOPLASTICI Dasatinib
Week 48 and 96 virologic outcomes in the EMERALD trial are provided in Table 6. 
Virološki ishodi u 48. i 96. tjednu ispitivanja EMERALD navedeni su u Tablici 6.
No clinically relevant differences in tenofovir alafenamide, or tenofovir pharmacokinetics were observed between healthy subjects and patients with severe renal impairment (eGFRCG > 15 but < 30 mL/min) in studies of tenofovir alafenamide. 
Nisu primijećene klinički značajne razlike u farmakokinetici tenofoviralafenamida ili tenofovira između zdravih ispitanika i bolesnika s teškim oštećenjem bubrežne funkcije (eGFRCG > 15 ali < 30 ml/min) u ispitivanjima tenofoviralafenamida.
No adjustment of methadone dosage is expected when initiating co-administration with Symtuza. 
Ne očekuje se prilagodba doze metadona kada se započinje njegova istodobna primjena s lijekom Symtuza.
Cobicistat increases serum creatinine due to inhibition of tubular secretion of creatinine without affecting renal glomerular function as assessed, for instance, by using Cystatin C (Cyst C) as filtration marker. 
Zbog inhibicije tubularne sekrecije kreatinina, kobicistat povisuje vrijednost serumskog kreatinina, ali pritom ne utječe na glomerularnu filtraciju određenu, primjerice, uz pomoć cistatina C kao biljega filtracije.
Treatment with darunavir/cobicistat 800/150 mg once daily during pregnancy results in low darunavir exposure (see Table 8). 
Liječenje darunavirom/kobicistatom od 800/150 mg primijenjenog jedanput na dan tijekom trudnoće rezultira niskom izloženošću darunaviru (vidjeti Tablicu 8).
The overall safety profile of Symtuza is based on data from a randomised, double-blinded, comparative Phase 2 trial, GS-US-299-0102 (N = 103 on darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), data from 2 Phase 3 trials TMC114FD2HTX3001 (AMBER, N = 362 on D/C/F/TAF) and TMC114IFD3013 (EMERALD, N = 763 on D/C/F/TAF), and on all available clinical trial and post-marketing data of its components. 
Ukupan sigurnosni profil lijeka Symtuza temelji se na podacima iz randomiziranog, dvostruko slijepog, usporednog ispitivanja faze 2, GS-US-299-0102 (N= 103 na darunaviru/kobicistatu/emtricitabinu/tenofoviralafenamidu [D/K/F/TAF]), podacima iz 2 ispitivanja faze 3 TMC114FD2HTX3001 (AMBER, N= 362 na D/K/F/TAF) i TMC114IFD3013 (EMERALD, N= 763 na D/K/F/TAF) i na svim dostupnim podacima za njegove sastavnice prikupljenima u kliničkim ispitivanjima i nakon stavljanja lijeka u promet.
Symtuza has not been studied in patients with severe hepatic impairment (Child-Pugh Class C), therefore, Symtuza must not be used in patients with severe hepatic impairment (see sections 4.3, 4.4 and 5.2). 
Symtuza nije ispitivan u bolesnika s teškim oštećenjem jetrene funkcije (Child-Pugh stadij C), stoga se Symtuza ne smije primjenjivati u bolesnika s teškim oštećenjem jetrene funkcije (vidjeti dijelove 4.3, 4.4 i 5.2).
Treatment with darunavir/cobicistat (two of the components of Symtuza) during pregnancy results in low darunavir exposure (see sections 4.4 and 5.2). 
Liječenje darunavirom/kobicistatom (dvije komponente lijeka Symtuza) tijekom trudnoće rezultira niskom izloženošću darunaviru (vidjeti dijelove 4.4 i 5.2).
At 48 weeks, 92% (46/50) achieved HIV-1 RNA < 50 copies/mL, similar to response rates in studies of treatment-naïve HIV-1 infected adults. 
HIV-1 RNK < 50 000 kopija/ml u 48. tjednu postiglo je 92% (46/50) bolesnika, što je slično stopama odgovora u ispitivanjima provedenima u prethodno neliječenih odraslih bolesnika zaraženih virusom HIV-1.
Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as darunavir, where bioavailability is limited and half-life is shortened due to CYP3A-dependent metabolism. 
Inhibicijom metabolizma posredovanog putem CYP3A kobicistat povećava sistemsku izloženost supstratima CYP3A, kao što je darunavir, koji zbog metabolizma ovisnog o CYP3A imaju ograničenu bioraspoloživost i skraćen poluvijek.
The intravenous clearance of darunavir alone (150 mg) and in the presence of low dose (100 mg) ritonavir was 32.8 l/h and 5.9 l/h, respectively. 
Klirens darunavira nakon njegove intravenske primjene samostalno (150 mg) i uz nisku dozu ritonavira (100 mg) iznosio je 32,8 l/h odnosno 5,9 l/h.
Following intravenous administration, the volume of distribution of darunavir alone was 88.1 ± 59.0 L (mean ± SD) and increased to 131 ± 49.9 L (mean ± SD) in the presence of 100 mg twice-daily ritonavir. 
Volumen distribucije samo darunavira nakon intravenske primjene iznosio je 88,1 ± 59,0 l (srednja vrijednost ± SD), a povećao se na 131 ± 49,91 (srednja vrijednost ± SD) uz primjenu sa 100 mg ritonavira dvaput na dan.
Clinical monitoring is recommended when co-administering Symtuza with beta-blockers and a lower dose of the beta-blocker should be considered. 
Kod istodobne primjene lijeka Symtuza i beta-blokatora, preporučuje se kliničko praćenje te treba razmotriti nižu dozu beta-blokatora.
In the Phase 3 study TMC114FD2HTX3001in treatment-naïve patients, Symtuza was associated with no or smaller reductions in bone mineral density (BMD) compared DRV/COBI+F/TDF as measured by DXA analysis of hip (LS means percent change: 0.17% vs -2.69%, p < 0.001) and lumbar spine (LS means percent change: -0.68% vs -2.38%, p =0.004) after 48 weeks of treatment. 
U ispitivanju faze 3 TMC114FD2HTX3001 kod bolesnika koji prethodno nisu bili liječeni, Symtuza nije bila povezana sa smanjenjima mineralne gustoće kostiju ili je bila povezana s manjim smanjenjima mineralne gustoće kostiju u usporedbi s DRV/KOBI+F/TDF, mjereno denzitometrijom (DXA) kuka (postotak promjene LS srednjih vrijednosti: 0,17% naspram -2,69%, p < 0,001) i lumbalne kralježnice (postotak promjene LS srednjih vrijednosti: -0,68% naspram -2,38%, p =0,004) nakon 48 tjedana liječenja.
Tenofovir alafenamide is a substrate of OATP1B1 and OATP1B3 in vitro. 
Tenofoviralafenamid je supstrat za OATP1B1 i OATP1B3 in vitro.
The pharmacokinetics of Symtuza have not been investigated in paediatric patients. 
Farmakokinetika lijeka Symtuza nije ispitivana u pedijatrijskih bolesnika.
This subject harbored a K103N mutation at screening, indicating transmitted NNRTI resistance. 
Taj je ispitanik imao mutaciju K103N pri probiru, što ukazuje na prijenos rezistencije na nenukleozidne inhibitore reverzne transkriptaze.
Clinical monitoring is recommended when co-administering Symtuza with perphenazine, risperidone or thioridazine. 
Preporučuje se kliničko praćenje kada se lijek Symtuza primjenjuje istodobno s perfenazinom, risperidonom ili tioridazinom.
For more details, refer to the prescribing information of darunavir and emtricitabine/ tenofovir alafenamide. 
Za više informacija vidjeti informacije o lijeku za darunavir i emtricitabin/tenofoviralafenamid.
Although darunavir has not been studied in patients with renal impairment, population pharmacokinetic analysis showed that the pharmacokinetics of darunavir were not significantly affected in HIV infected patients with moderate renal impairment (eGFRCG between 30-60 mL/min, N = 20) (see sections 4.2 and 4.4). 
Iako darunavir nije ispitivan u bolesnika s oštećenjem bubrežne funkcije, populacijska farmakokinetička analiza pokazala je da u bolesnika zaraženih HIV-om koji su imali umjereno oštećenje bubrežne funkcije nije bilo značajnog utjecaja na farmakokinetiku darunavira (eGFRCG između 30 i 60 ml/min, N = 20) (vidjeti dijelove 4.2 i 4.4).
The 725 patients in total had a median age of 34 years (range 18-71), 88.3% were male, 83.2% White, 11.1% Black, 1.5% Asian. 
Medijan dobi ukupno 725 bolesnika bio je 34 godine (raspon 18-71), 88,3% bilo je muškog spola, 83,2% bijele rase, 11,1% crne rase, 1,5% azijskog porijekla.
Risperidone 
Risperidon
Rifabutin Rifapentine 
Rifabutin Rifapentin
Because there is a lower tenofovir exposure in rats and mice after the administration of tenofovir alafenamide compared to tenofovir disoproxil, carcinogenicity studies and a rat peri-postnatal study were conducted only with tenofovir disoproxil. 
Budući da je izloženost tenofoviru u štakora i miševa nakon primjene tenofoviralafenamida manja nego kod primjene tenofovirdizoproksila, ispitivanja kancerogenosti te perinatalno i postnatalno ispitivanje u štakora provedena su samo za tenofovirdizoproksil.
The use of Symtuza in ART-naïve adolescent patients from the age of 12 years to < 18 years, and weighing at least 40 kg is supported by two trials in HIV-1 infected paediatric patients (TMC114-C230 and GS-US-292-0106). 
Primjenu lijeka Symtuza u adolescenata u dobi od 12 do < 18 godina i tjelesne težine od najmanje 40 kg koji se prethodno nisu liječili antiretrovirusnom terapijom podupiru dva ispitivanja provedena u pedijatrijskih bolesnika zaraženih virusom HIV-1 (TMC114-C230 i GS-US-292-0106).
Therapeutic drug monitoring of voriconazole, posaconazole or itraconazole is recommended. 
Preporučuje se terapijsko praćenje koncentracije vorikonazola, posakonazola ili itrakonazola.
Do not take Symtuza - if you are allergic (hypersensitive) to darunavir, cobicistat, emtricitabine, tenofovir alafenamide, or any of the other ingredients of Symtuza (listed in section 6). 
Nemojte uzimati lijek Symtuza - ako ste alergični (preosjetljivi) na darunavir, kobicistat, emtricitabin, tenofoviralafenamid ili bilo koji drugi sastojak lijeka Symtuza (naveden u dijelu 6.) - ako imate teške jetrene tegobe.
No dose adjustment of Symtuza is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, however, Symtuza should be used with caution in these patients, as the darunavir and cobicistat components of Symtuza are metabolised by the hepatic system. 
Nije potrebno prilagođavati dozu lijeka Symtuza u bolesnika s blagim (Child-Pugh stadij A) ili umjerenim (Child-Pugh stadij B) oštećenjem jetrene funkcije, međutim, u ovih se bolesnika Symtuza treba primjenjivati uz oprez jer se darunavir i kobicistat, sastavnice lijeka Symtuza, metaboliziraju putem jetre.
Emtricitabine triphosphate inhibits HIV replication through incorporation into viral DNA by the HIV reverse transcriptase (RT), which results in DNA chain-termination. 
Emtricitabin trifosfat inhibira replikaciju HIV-a ugradnjom u virusnu DNK uz pomoć reverzne transkriptaze (RT) HIV-a, što dovodi do prekida lanca DNK.
How to take Symtuza 
Kako uzimati lijek Symtuza